Veradermics
MANE
165 hedge funds and large institutions have $4.17B invested in Veradermics in 2026 Q2 according to their latest regulatory filings, with 97 funds opening new positions, 41 increasing their positions, 19 reducing their positions, and 14 closing their positions.
593% more first-time investments, than exits
New positions opened: 97 | Existing positions closed: 14
263% more capital inflows, than outflows
Capital inflows: $1.08B | Capital outflows: $297M
116% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 19
104% more funds holding
Funds holding: 81 → 165 (+84)
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
7.22% more ownership
Funds ownership: 74.03% → 81.25% (+7.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
+$141M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$132M |
| 3 |
BlackRock
New York
|
+$123M |
| 4 |
D.E. Shaw & Co
New York
|
+$82.4M |
| 5 |
Maverick Capital
Dallas,
Texas
|
+$74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$51.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$38.3M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$34.1M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$34M |
| 5 |
Paradigm Biocapital Advisors
New York
|
-$33.2M |
MANE Hedge Fund Activity: Q2 2026 in Review
165 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Veradermics (MANE) for Q2 2026, worth a combined $4.17B — up 155% from $1.64B a quarter earlier.
Buyers outnumbered sellers: 97 funds opened new MANE positions and 14 closed out — a net gain of 83 holders — while 41 added to existing stakes and 19 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $141M. The largest seller was Adage Capital Partners, cutting an estimated $51.5M.
- 165 institutional investors held Veradermics (MANE) as of Q2 2026, up from 81 in Q1 2026.
- Funds reported $4.17B of Veradermics stock for Q2 2026, up 155% quarter-over-quarter.
- 97 funds opened new Veradermics positions in Q2 2026 and 14 closed out, a net change of +83 holders.
- The largest Veradermics buyer in Q2 2026 was Deep Track Capital, an estimated $141M added.
- The largest Veradermics seller in Q2 2026 was Adage Capital Partners, an estimated $51.5M sold.
Based on aggregated 13F filings for Q2 2026.